Member Info for gjbrandon

@newuncle yes, you read way too much into those sentences. AIM is a strange place that at tines is totally unrelated to the underlying company. Wait and see the Interims and chillax

@Chesh, the market will do what the market wants to do. The DeepVerge Group team continue to grow at a pace even I did not expect some 3 years ago. The business model formula works and at some point, whether it is CR, Skin Trust Club, Labskin, AI, Data Analytics and every other revenue generation platform that hits the bottom line, in time it will be a much bigger company this time next year. .... And the market will do what the market does.

lol... Don't put words in my mouth. The core philosophy of DeepVerge is partner, collaborate and cooperate. That's how we grow quickly. We are not going to shift an existing infrastructure overnight. It makes no sense, purely because the incumbent facilities work (not quickly enough) but they work according to the minimum requirement. To change that you have to cooperate and move the minimum requirement higher. That requires working with existing partners who are on the ground. Modern Water Inc has been in the USA for nearly 40 years. Past problems included a lack of resources. It meant customers had to order, pay a deposit and wait for production. That has changed since the merger. Now, equipment is available off the shelf, for the first time in decades.

Only Modern Water offers three acute toxicity analyzers that detect over 2,700 hazardous chemicals and compounds. The award-winning Microtox LX extends Modern Water’s leadership in acute toxicity testing. Municipalities and industrial companies in the US and worldwide have incorporated Microtox toxicity testing into their water safety testing protocols because of its accuracy, repeatability, and ability to provide rapid results. We are just building on that, with existing partners and joining with new ones

Why Grab and Composite. A previous comment indicated the need to negotiate the rate of collection and testing whether it is a weekly composite/grab and transport, or every 15 minutes. The evolution of wastewater epidemiology continues and will continue to move forward and there is little doubt that DeepVerge and Modern Water will play a role. Patience is required, not just to close the deals, but to work with existing stakeholdres doing the grab and composite. Everyone must win, or at the very leasdt appear not to lose face.

Comments on customers. We have no reason to give a day to day update on our agreements unless any of them exceed our material threshold. Likewise unless any agreement is terminated we have no reason to announce it. The only thing that matters is targets being met with existing and new clients and the rate of growth continues at triple digit growth year on year. If that changes we will inform the market.

@Frix

B2B2C and preparation of the marketing program, sales channels and working with global marketing partner (to be announced shortly) takes time to pull all together and absolutely critical that we get it right, which is why we brought Niamh O'Kennedy, former director in Ogilvy to take the marketing helm. Everything you mentioned is correct and almost ready to kick off.

@Paulcon2021 I am on facebook, but not in the DVRG F/Book Chat Group or the Telegram Group which I get invited to quite a lot, but purposely stay away.

@T.Rat the testing protocols are different, requiring different ethical committees with different conditions. That is the most appropriate means of answering in a public forum. @Davidlaw addresses a lot of issues relating to bureaucracy, regardless of how well the technology works, there are so many hurdles from concept last June to market for any medical device. Wastewater will roll out much faster and we have informed the market of an update this quarter

I believe some may have (hopefully) overlooked or forgot, references in many RNS to the Breath test as recently as June 30th less than 2 months ago. https://irpages2.equitystory.com/websites/rns_news/English/1100/news-tool---rns---eqs-group.html?iframe=true&article=31956836&company=Deepverge&iframe=true

40 subject breath test clinical trial concluded at Royal College of Surgeons, Ireland

o 16 independently confirmed as COVID-19 positive with PCR tests

o Breath samples were tested on the Microtox® BT nano-optofluidic chip surface with Affimer® reagents ("Avacta Group") and Optimers ("Aptamer Group")

o Detection of the live virus confirmed indicating 9 times increase in digital spectrum signal on the Microtox® BT compared to control

o Microtox® BT delivered results in under 60 seconds from breath samples

o Subject to successful completion of additional human trials, the Microtox BT would be expected to meet the criteria for UK, MHRA's Target Product Profile Rapid Breath Test with potential roll-out of COVID-19 and other pathogen breath tests later this year.

@Glebewhite, not everyone who reads the RNS are shareholders or investors and marketing new technologies and advances for existing and new clients play an important part to ensure that business development provides those additional sales. This is a business for all stakeholders.

Always an interesting time of the year when comments on a single bulletin board outnumber trades by 25% half way through the day.

@T.Rat - 60 Countries.

@Gidget with Dulux paint. Maybe not funny, but I have to lighten the mood. The teams, from all divisions are involved at every level to close multiple partnerships and deals. As negotiations progress, opportunities and details alter, but unless there is any material change to the fundamental content of the MoU signed with China Resources (which it hasn't) that would require an RNS, then there is no reason to speculate otherwise. The same goes for other contracts, partnerships for MicrotoxPD installations in jurisdictions outside of China that are under NDA.

So I urge you to try to enjoy the weather, as summer's do not last too long in UK, and let the normal business do what it has been doing well for 3 years, create value.

@asqn34 - Good article and why China Resources has an interest in a deal with Deepverge and the Modern Water MicrotoxPD technology

@MMA_Hemp thank you for taking the time to think things through. The first part is easy. Any product can be part of the Labskin recommended list once they have been tested to address the underlying conditions associated with an individuals test results. Those products recommended have been tested.

Lymes disease I am familiar with, but have not had any discussion internally on that. Most certainly it would be a Microsaic point of care diagnostic solution if it were to be addressed.

You are correct about the over use of antibiotics and unnecessary prescriptions. This is something that should form part of the point of care diagnosis, again with Microsaic tools and is already described as the Digital Health Revolution development programme underway for GP clinics.

Not that I would be a seller here, knowing what I know, but 6th of August is 3 years since Camillus and I stepped into Integumen with a share price hovering between 0.5p and 0.8p (consolidated by 10 to 5p and 8p). Prior to that a previous funding round with EIS tax advantages, from January 2018, would have reached their 3 year threshold from early this year, unlocking those investors.

We have no understanding of who is selling or why, but our business strategy of multiple revenue streams, expanding by increasing revenues per client is working and the share price since 2018 has grown from 5 pence to where it is today.

In early presentations, May 2019 at the Investor evening in the NED Hotel in London, for instance, I stated quite clearly that we will be growing by organic and M&A. We'll, we have delivered on everything we set out to and continue to see the fruits of that strategy.

So we have grown before and during the pandemic and the speed does not appear to be slowing and we are only at the beginning. So settle in for the next stage of the journey.

5p to 30p
£274k in 2018
£10m guided in 2021, so far.
5 employees in 2018
57 in 2021 and adding.

It's good to have diverse opinions and reasoned debate on the board, but negative arguments simply fall away with each milestone promised, guided and delivered on overtime, not overnight. Do your research, read RNS, annual and interim reports that have been audited and speak with management. If you take advice from anything on a bulletin board, you are way behind the person writing it as they are not inside to anythi g in the company, or ill-informed and likely to lose your investment. Its okay to believe, but you have to verify.

Gerry

@Roly12 if you were here a year you would be up 56% or 256% if you were here 3 years, so not sure if your timing is correct. We are building a company and that takes time. Sorry you felt a need to sell out, but question this comment which can be looked up in a historical quote

Broker managed for multiple parties

They are more likely to be Bed & ISA transactions locked in at these prices.

Hi Barrett. You could look at the www.deepverge.com/investors/ page in the news section which is reserved for shareholders and investors and with all RNS, goes live the instant it is released to the Regulatory News Service of the Stock Exchange.

The News section on the Deepverge website is dedicated to news about the subsidiaries

@Newuncle while I come in and read, there are things I do often need to clarify, purely on information that is out there, but incorrectly stated here. It is not a book that would be in everyone's summer poolside reading but the FCA Handbook on Rules of Disclosure is the definitive book on Disclosure Rules for Institutional Investors in any Placing.

An Institutional Investor is not required to issue a TR1 under disclosure rules and transparency rules FCA handbook Section 5.1 notification of the acquisition or disposal of major shareholdings where notification of certain voting rights are to be disregarded based on the thresholds reached by a vote holder under the notification rules for the following reason:

5.1.3 Subsection 4: (4)(a) shares held by an investment firm, provided that the voting rights attached to such shares do not exceed 5% and the voting rights attached to shares are not exercised or otherwise used to intervene in the management of the issuer.

No TR1 was required for an investment firm with up to 5%, not 3% in the recent placing under VCT conditions